|
Along
Interview With Geert Vanden Bossche PhD, DVM Along with this video, I've included Geert Vanden Bossche's professional biography and two more related articles below. I highly recommend you read them ! As a scientist Geert Vanden Bossche has been a full member of the vaccine development world - but one who takes risks and potential downsides of vaccines particularly seriously. He's deeply concerned at our response to COVID-19 so far - and calls urgently for a change of course. The change called for, however, is first of all a scientific one. Stepping back from hasty, fear-based or politicized policies and decisions : "I am herewith posting a list of a series of publications that have been instrumental in providing enlightening insights on the interplay between Covid-19 and the host immune system. They provide so to speak critical pieces of the puzzle that I have been putting together. Entire puzzles are rarely published. That’s why publications rarely bring solutions to complex problems. For your convenience, I have allocated the publications I consulted to different categories. As you will appreciate, I have been tapping into several disciplines. To ‘solve’ a problem as complex as a viral pandemic, one has to draw from several different fields, including epidemiology, (molecular) biology, virology, immunology, genetics, vaccinology and even biophysics. Again, this is why ‘finished’ puzzles cannot be found in science journals specifically dedicated to a specific field of interest." At the end of the second article below, he finishes with : "I only take responsibility for the statements and scientific papers that I have published myself. I want to emphasize that what I am trying to convey goes beyond various beliefs and opinions. They are irrelevant to what concerns us as humans. In fact, they are an obstacle. Above all I want to safeguard my integrity and insist on absolute independence. The response to my appeal should remain only and purely scientific and in no occasion ever be used or abused by any non-scientific rhetoric." Interview, articles, credentials, recommendations - urgent recommendations. I encourage you to study these thoughts and call to action ; and to share and take action on them in the spirit they're given ! Executive Summary and Supporting Articles : Geert Vanden Bossche 
Addendum to Executive Summary March 17, 2021
About Geert Vanden Bossche Experience Company Name : VARECO Dates Employed : Sep 2012 – Present Employment Duration : 8 yrs 7 mos Location : Europe Independent vaccine consultant with a long-standing track record in Academia, Vaccine Industry and Global Health (GH) ; providing support on vaccine project management as well as advice, guidance and expert opinion on preclinical development of vaccines & biologicals, from project selection up to IND. Assignments include prophylactic and therapeutic vaccine projects in Human and Veterinary Vaccine Industry, Small Biotech, Global Health organizations in the US or Europe My knowledge, insights and skills cover a diversified spectrum of Life Science domains including : - Life Science Project Management (in early and late dvpt) - Due diligence on technologies & processes related to vaccines, adjuvants and biologicals - Patent writing and strategic IP management - Guidance on regulatory requirements to CMC documentation, DMF files - Target product profiling and SWOT analysis - Infectious and immune-mediated diseases including their (immune) pathogenesis and epidemiology - Host-pathogen interactions and mechanisms of immune escape - Innate and adaptive immunology (both, humoral and cell-mediated) - Antigen discovery - Preclinical vaccine development (including animal experimentation as well as immunological and physicochemical characterization of vaccines and biologicals) - Vaccine formulation science and modern vaccine delivery technologies (incl. devices) ; modern technologies for enhancement of antimicrobicidal activity in multidose vaccines - Small-scale pre-GMP vaccine manufacturing (incl. synthetic chemistry of Ag or adjuvant, recombinant Ag expression, viral vectors, upstream and downstream processing) To enhance the quality and capacity of my consultancy services, I leverage an extensive network of professional contacts providing direct access to US and European governmental and regulatory agencies, Academia and Research Institutions, Human and Veterinary Vaccine Industry, Global & Public Health organizations and CROs in the US and Europe Company Name : German Centre for Infection Research (DZIF) Dates Employed : Aug 2017 – Feb 2018 Employment Duration : 7 mos Location : Cologne, Germany Spearheading a portfolio of translational vaccine research projects, conducted at German universities and research centres sponsored by DZIF. Holding overall accountability for strategic alignment of translational infection research in support of preclinical and early clinical testing Developing a trans-academic translational network for Vaccine development totaling eight universities and research organizations across Germany Company Name : Univac Dates Employed : Nov 2014 – Nov 2016 Employment Duration : 2 yrs 1 mo Location : HuldenbergI I founded Univac as inventor of a new vaccine technology which I subsequently further developed as CSO of the Company. The technology enables the development of universal vaccines educating the host immune system to redirect immune targeting away from canonical antigens to a widely divergent spectrum of vitally vulnerable pathogen-derived ‘self-mimicking’ antigens, irrespective of MHC polymorphism. Although ‘non-self’ and exposed on the surface of infected or pathologically altered cells, these antigens are not effectively recognised upon natural infection or disease. This new type of vaccines harnesses the power of the immune system by unlocking the untapped potential of self-centered Natural Killer (NK) cells capable of recognising these unconventional antigens. The resulting type of immune response is unprecedented and licenses the host immune system to readily eliminate infection or to cure disease across a broad range of unrelated pathogens and/ or mammalian species. This sharply contrasts with conventional targeting of natural immune responses as induced by conventional vaccines. Because of their fast (NK cells) and universally protective effect, Univac vaccines are uniquely suited to prevent pathogenic agents from escaping host immune responses as of an early stage of infection or immune-mediated disease. The technology obviates the need for traditional adjuvants, multiple boost injections or expensive manufacturing processes and is readily compatible with intradermal or mucosal administration. Hence, it also offers unprecedented advantages in terms of safety, convenience and cost-effectiveness Company Name : Global Alliance for Vaccines and Immunisation (GAVI) Dates Employed : Mar 2015 – Mar 2016 Employment Duration : 1 yr 1 mo Location : Geneva Area, Switzerland During my term at GAVI, I coordinated GAVI’s Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidate(s) that suitably meet the requirements for use in an Ebola epidemic. In this capacity, I also contributed to several workshops aimed at proposing novel and efficient approaches to improving preparedness in cases of Global Health Emergencies of international concern Company Name : Positions in Academia Dates Employed : Sep 1980 – Sep 2015 Employment Duration : 35 yrs 1 mo Location : Belgium - Germany Training in Veterinary Medicine at the faculty Notre-Dame-de-la-Paix and the State University of Ghent (1980-1983) - Doctoral degree in Veterinary Medicine from State University of Ghent (1983) - Postdoctoral training in Equine Medicine and Surgery at the Free University of Berlin, Germany (1984-1987) - Postdoctoral Fellowship in Virology at James A. Baker Institute for Animal Health, Cornell University, Ithaca, NY 14850, USA (Sept 1990- mid 1991) - Research scientist in Virology, Immunology and Molecular Biology at the Robert Koch Institute in Berlin, Germany (1987- 1990) - Board certified in Veterinary Virology (1990) - Senior Research Scientist and Head of Environmental Virology at University of Hohenheim, Stuttgart, Germany (1990-1994) - Board certified in Veterinary Microbiology and Animal Hygiene (1992) - Visiting Professor in Environmental Virology at the European Faculty for Environmental Sanitation (1998-2004) - Adjunct Professor in Environmental Virology and Zoonotic Diseases at University of Hohenheim, Stuttgart, Germany (1997-2000) - Visiting Scientist at the REGA Institute, KU Leuven, Belgium (2013 - 2015) Company Name : Bill & Melinda Gates Foundation (BMGF) Dates Employed : May 2008 – Jun 2011 Employment : Duration3 yrs 2 mos Location : Seattle, Washington 98102, USA Responsible for operating Vaccine Programs (e.g., HIV-1, Malaria, TB, Polio) and establishing international product development partnerships for immune interventions in Global Health (e.g., with Academia, Biotech Industry, NIH, Welcome Trust, WHO, PATH). Coordinating and spearheading international collaborations and consortia on innovative vaccine approaches and steering multidisciplinary vaccine initiatives Company Name : Solvay Biologicals Dates Employed : Jul 2007 – May 2008 Employment Duration : 11 mos Location : Weesp, the Netherlands Responsible for leading the operational aspects of an interdisciplinary project team including the planning and implementation of adjuvanted Influenza vaccines that enable dose sparing. Implementation of commercial-scale production of cell-based methods and expansion of Influenza vaccine production capacity such as to meet DHSS (U.S. Department of Human Health Services) contractual requirements (Pandemic Influenza Preparedness Plan) Company Name : Novartis Vaccines & Diagnostics Dates Employed : Aug 2006 – Jul 2007 Employment Duration : 1 yr Location : Siena, Italy & Emeryville, USA Vaccine Research Program/Adjuvant Program responsibilities : - Project leader of NVD's RSV vaccine project (Respiratory Syncytial Virus) - Coordinator of preclinical activities on combined seasonal RSV-Influenza vaccine or elderly & high risk adults - Responsible for defining and shaping the scope and strategy of NVD's adjuvant and vaccine delivery technologies including management of NVD’s adjuvant portfolio, opportunity sourcing, and establishment of an internal interdisciplinary due diligence team for the evaluation of relevant extramural opportunities Company Name : Glaxo Smith Kline Biologicals Dates Employed : May 2001 – May 2006 Employment Duration : 5 yrs 1 mo Location : Rixensart, Belgium - Research Program Leader on Vaccine Formulation Development & Alternative Deliveries and in charge of biophysical characterization activities on adjuvanted vaccine formulations. - Coordination and follow-up of extramural contracts & collaboration agreements on new immunization strategies and innovative vaccine adjuvant, delivery or formulation technologies (e.g., co-delivery, mucosal, subcutaneous, intradermal immunization) - Development and validation of vaccine and adjuvant characterization assays - Study of adjuvant-antigen interaction and of adjuvant structure-function relationship - Coordination and resource management of preclinical activities including CMC section of INDs and cGMP production of (adjuvanted) vaccine candidates - Planning laboratory activities and establishing outside collaborations with academia Total Duration : 6 yrs 4 mos Title : Senior Project Leader ‘Adolescent Vaccine Projects Dates Employed : Jun 1998 – May 2001 Employment Duration : 3 yrs Location : Rixensart, Belgium Major responsibilities : - Project Management on Raw Material Traceability (RAMATRA) and vaccine projects in Late Development, e.g., Herpes Simplex Virus type 2, Hepatitis B, Streptococcus Pneumoniae and Enterotoxic Escherichia Coli (in collaboration with SBL Vaccines, Sweden)
Employment Duration : 3 yrs 4 mos Location : Rixensart, Belgium Major responsibilities (3 direct reports ; 6 technicians) : - Management and coordination of vaccine product development, optimization as well as validation of analytical methods in accordance with regulatory requirements or guidelines and vaccine marketing constraints - Budget management of all activities related to QC assay development - Transfer from R&D and further development of new QC-relevant characterization techniques on new vaccine candidates (e.g., HSV-2 vaccine, Lyme disease vaccine); contacts with national/international regulatory and health authorities (e.g., FDA, NIBSC, IHE, WHO) on technical dossiers ; active participation in pre-IND meetings Source of Geert Vanden Bossche profile : LinkedIn.com
Share this page
with friends !
1 Comment
Sandy Hadenfeld
10/14/2022 08:14:03 am
I was tested HSV2 positive and ever since then i have been taking different kinds of medicine but yet no improvement until i saw testimonies on the internet of how Robinson buckler has been curing different people from different kinds of diseases, immediately i contacted him. After our discussion he prepared the medicine and send it to me, which i received and took according to his instructions. Now my doctor just confirmed me HSV2 negative. My heart is so filled with joy, thank you so much Robinson buckler for curing me. If you are reading this and you are suffering from HSV or any other disease you can contact Robinson buckler on this Email address: [[email protected] 💫🖤💫🖤💫🖤💫🖤💫🖤💫🖤💫🖤💫🖤 Leave a Reply. |
AuthorJeff Smith RN, born 1950. A registered nurse since 1984 - but holistic in my outlook to health since probably around 1968. Living Waters Wellness considers not just the health of the physical body, but our soul and spirit, our social forms, our environment - and as a matter of fact, our whole earth. It's a new website, and a work in progress - but by all means, have a look around ! Archives
September 2024
Categories |
||||
RSS Feed